GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Intelligent Bio Solutions Inc (NAS:INBS) » Definitions » Intrinsic Value: Projected FCF

Intelligent Bio Solutions (Intelligent Bio Solutions) Intrinsic Value: Projected FCF : $0.00 (As of May. 23, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Intelligent Bio Solutions Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-05-23), Intelligent Bio Solutions's Intrinsic Value: Projected FCF is $0.00. The stock price of Intelligent Bio Solutions is $2.305. Therefore, Intelligent Bio Solutions's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Intelligent Bio Solutions's Intrinsic Value: Projected FCF or its related term are showing as below:

INBS's Price-to-Projected-FCF is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.755
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Intelligent Bio Solutions Intrinsic Value: Projected FCF Historical Data

The historical data trend for Intelligent Bio Solutions's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intelligent Bio Solutions Intrinsic Value: Projected FCF Chart

Intelligent Bio Solutions Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial - - - - -

Intelligent Bio Solutions Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Intelligent Bio Solutions's Intrinsic Value: Projected FCF

For the Medical Devices subindustry, Intelligent Bio Solutions's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intelligent Bio Solutions's Price-to-Projected-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Intelligent Bio Solutions's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Intelligent Bio Solutions's Price-to-Projected-FCF falls into.



Intelligent Bio Solutions Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)



Intelligent Bio Solutions  (NAS:INBS) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Intelligent Bio Solutions's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=2.305/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Intelligent Bio Solutions Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Intelligent Bio Solutions's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Intelligent Bio Solutions (Intelligent Bio Solutions) Business Description

Traded in Other Exchanges
Address
57th Street, 142 West, 11th Floor, New York, NY, USA, 10019
Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana.
Executives
Harry Simeonidis director, officer: CEO, President 708 THIRD AVENUE, 6TH FLOOR, NEW YORK CITY NY 10017
Foundation Ma-ran 10 percent owner 1908 CLIFF VALLEY WAY NE, ATLANTA GA 30329
Gary W. Rollins Foundation 10 percent owner 1908 CLIFF VALLEY WAY NE, ATLANTA GA 30329
David A Jenkins director P.O. BOX 682838, PARK CITY UT 84068
Jason Isenberg director 1908 CLIFF VALLEY WAY NE, ATLANTA GA 30329
Spiro Kevin Sakiris officer: Chief Financial Officer 708 THIRD AVENUE, 6TH FLOOR, NEW YORK CITY NY 10017
Life Science Biosensor Diagnostics Pty Ltd 10 percent owner LEVEL 9, 85 CASTLEREAGH STREET, SYDNEY C3 2000
Tom Parmakellis director 708 THIRD AVENUE, 6TH FLOOR, NEW YORK CITY NY 10017
Victoria Gavrilenko director 708 THIRD AVENUE,, 6TH FLOOR, NEW YORK CITY NY 10017
Christopher Towers director 1981 MARCUS AVENUE, SUITE 130, LAKE SUCCESS NY 11042
Lawrence B Fisher director C/0 FINANCIAL FEDERAL CORP, 733 THIRD AVENUE, NEW YORK NY 10017
Leonard Victor Kempler director 708 THIRD AVENUE,, 6TH FLOOR, NEW YORK CITY NY 10017
George Margelis director 708 THIRD AVENUE, 6TH FLOOR, NEW YORK CITY NY 10017
Boyages Steven Constantine director 708 THIRD AVENUE,, 6TH FLOOR, NEW YORK CITY NY 10017
Jonathan Scott Hurd director 708 THIRD AVENUE,, 6TH FLOOR, NEW YORK CITY NY 10017

Intelligent Bio Solutions (Intelligent Bio Solutions) Headlines

From GuruFocus